literature

HIV mutation literature information.

NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.

PMID: 17640745 2007 Antiviral research

Abstract: High-level resistance to nevirapine and moderate level resistance to both stavudine and zidovudine were associated with G190S/A/E substitutions.

Abstract: Interestingly, the simultaneous presence of G190S and T215Y was associated with a reduction in the impairment of the G190S-mutated enzyme.

Abstract: On the other hand, G190S was associated with a marked decrease in RT catalytic efficiency, while T215Y showed a more limited effect.

Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.

PMID: 17926645 2007 Antiviral therapy

Abstract: In a regression model adjusted for CD4+ T-cell count, HIV RNA, year of TCF, age, gender and previous inferior antiretroviral therapy, harbouring > or =9 versus < or =8 mutations was associated with increased mortality (mortality rate ratio [MRR] 2.3 [95% confidence interval (CI) 1.1-4.8]), as were the individual mutations T215Y (MRR 3.4 [95% CI 1.6-7.0]), G190A/S (MRR 3.2 [95% CI 1.6-6.6]) and V82F/A/T/S (MRR 2.5 [95% CI 1.2-5.3]).

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

PMID: 18052601 2007 PLoS medicine

Result: N348I was highly associated with several key drug resistance mutations, including M184V/I (p = 6.6 x 10-45) the TAMs M41L (p = 1.8 x 10-14), D67N (p = 7.7 x 10-10), K70R (p = 1.4 x 10-10), T215Y/F (p = 6.0 x 10-21), K219Q/E (p = 8.0 x 10-4), and L210W (p = 0.002), and the NNRTI resistance mutations K103N (p = 1.1 x 10-19), V108l (p = 8.4 x 10-13), Y181C/I (p = 4.7 x 10-13) and G190A/S (p = 8.0 x 10-9) (Figure 1).

Discussion: In our cohort N348I was associated with the appearance of

Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.

PMID: 16504235 2006 Virology

Abstract: In the absence of efavirenz, the fitness hierarchy was G190S < G190A < K103N < wild-type.

Abstract: It also suggests that high concentrations of efavirenz are unlikely to favor the selection of G190S clinically.

Abstract: The fitness reduction of G190S relative to K103N was less evident at high efavirenz concentrations, although K103N still replicated more efficiently.

Abstract: We evaluated the replication efficiency of the HIV reverse transcriptase (RT) mutants K103N, G190A, and G190S, which confer resistance to the non-nucleoside

PMID: 15608517 2005 Journal of acquired immune deficiency syndromes (1999)

Abstract: There were differences between CRF01_AE and subtype B viruses in several drug resistance mutations including the following: D67N, L210F, K101E, V106M, V179I/D, G190A/S/E, and G48V (which were more common in CRF01_AE virus) and M41L, T215Y, and V82A (which were less common in CRF01_AE virus).

Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.

PMID: 15668550 2005 AIDS (London, England)

Abstract: At month 6, the mutations detected were K65R, L74V, L100I, K103N/R/T, Y181C and G190E/Q/S.

Early virological failure with a combination of tenofovir, didanosine and efavirenz.

PMID: 15751775 2005 Antiviral therapy

Abstract: At failure, G190S/E alone or associated with K103N and K101R mutations was detected in five patients, and K103N/L1001/V108l in the sixth patient.

4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.

PMID: 15771439 2005 Journal of medicinal chemistry

Abstract: When tested further, it was shown that these molecules, and in particular compound 35, are globally more active than 9, 10, and efavirenz against an additional eight single [L100I, K101E, V106A, E138K, V179E, G190A/S, and F227C] and four double HIV mutant strains [L100I + K103N, K101E + K103N, K103N + Y181C, and F227L + V106A], which are clinically relevant.

Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs.

PMID: 19825125 2005 Journal of the International AIDS Society

Table: G190S

Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women.

PMID: 12571524 2003 Journal of acquired immune deficiency syndromes (1999)

Abstract: The primary mutation, G190S, conferring resistance to NNRTIs was present in 1 patient.

Browser Board

Co-occurred Entities

Filtrator